Clinical trial
12 Week,Comparing Safety of HMR1964 & Insulin Aspart Used in Continuous…
NCT00046150 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00046150 |
|---|---|
| Title | 12 Week,Comparing Safety of HMR1964 & Insulin Aspart Used in Continuous Subcutaneous Infusion in Type 1 Diabetes. |
| Official title | 12-Week, Multinational, Multicenter, Controlled, Open, 1:1 Randomized, Parallel Clinical Trial Comparing the Safety of HMR1964 and Insulin Aspart Used in Continuous Subcutaneous Insulin Infusion (CSII) in Subjects With Type 1 Diabetes Mellitus |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes, Type I |
| Intervention type | Drug |
| Interventions | Insulin glulisine (HMR1964) |
| Enrollment | 59 |
| Start date | May 1, 2002 |
| Completion | Dec 1, 2002 |
| First posted | Sep 23, 2002 |
| Last update posted | Jun 19, 2008 |
| Countries | France, Germany, Netherlands |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: